Mary-Louise Rogers Selected Research

Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)

1/2022	Urinary neopterin: A novel biomarker of disease progression in amyotrophic lateral sclerosis.
7/2019	Removal of p75 Neurotrophin Receptor Expression from Cholinergic Basal Forebrain Neurons Reduces Amyloid-β Plaque Deposition and Cognitive Impairment in Aged APP/PS1 Mice.
11/2017	Urinary Extracellular Domain of Neurotrophin Receptor p75 as a Biomarker for Amyotrophic Lateral Sclerosis in a Chinese cohort.
3/2017	Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS.
2/2016	Inhibition of motor neuron death in vitro and in vivo by a p75 neurotrophin receptor intracellular domain fragment.
1/2014	The extracellular domain of neurotrophin receptor p75 as a candidate biomarker for amyotrophic lateral sclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mary-Louise Rogers Research Topics

Disease

7	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2022 - 01/2012
5	Disease Progression 01/2022 - 01/2014
2	Neuroblastoma 11/2015 - 05/2013
2	Lymphoma (Lymphomas) 11/2015 - 05/2013
2	Neoplasms (Cancer) 09/2015 - 05/2013
1	Melanoma (Melanoma, Malignant) 01/2021
1	Cognitive Dysfunction 07/2019
1	Alzheimer Disease (Alzheimer's Disease) 07/2019
1	Wounds and Injuries (Trauma) 02/2016
1	Multiple Sclerosis 01/2014
1	Parkinson Disease (Parkinson's Disease) 01/2014
1	Glioblastoma (Glioblastoma Multiforme) 05/2013
1	Brain Injuries (Brain Injury) 07/2006
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2006

Drug/Important Bio-Agent (IBA)

6	Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA 01/2022 - 01/2014
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2014
3	AntibodiesIBA 01/2021 - 05/2013
3	Pharmaceutical PreparationsIBA 11/2015 - 05/2013
2	Biological ProductsIBA 03/2017 - 01/2016
1	NeopterinIBA 01/2022
1	abacavir, dolutegravir, and lamivudine drug combinationIBA 11/2019
1	lamivudine drug combination abacavir FDA Link 11/2019
1	dolutegravirIBA 11/2019
1	Amyloid (Amyloid Fibrils)IBA 07/2019
1	Cholinergic Agents (Cholinergics)IBA 07/2019
1	Protein Isoforms (Isoforms)IBA 01/2016
1	EpitopesIBA 01/2016
1	Superoxide Dismutase-1IBA 08/2015
1	CreatinineIBA 01/2014
1	CamptothecinIBA 05/2013
1	SiliconIBA 05/2013
1	Rituximab (Mabthera)FDA Link 05/2013
1	Nerve Growth Factors (Neurotrophins)IBA 07/2006

Therapy/Procedure

2	Therapeutics 01/2022 - 01/2012
1	Art Therapy 11/2019